Publications 2018

287.

Frantzi M, Latosinska A, Belczacka I, Mischak H.

Urinary proteomic biomarkers in oncology: ready for implementation?

Expert Rev Proteomics. 2018 Nov 9. doi: 10.1080/14789450.2018.1547193. [Epub ahead of print]

PMID: 30412678

View Abstract:   Request Reprint

 

286.

Rodríguez-Ortiz ME, Pontillo C, Rodríguez M, Zürbig P, Mischak H, Ortiz A.

Novel Urinary Biomarkers For Improved Prediction Of Progressive Egfr Loss In Early Chronic Kidney Disease Stages And In High Risk Individuals Without Chronic Kidney Disease.

Sci Rep. 2018 Oct 29;8(1):15940. doi: 10.1038/s41598-018-34386-8.

PMID: 30374033

View Abstract:   Request Reprint

 

285.

Kanzelmeyer NK, Zürbig P, Mischak H, Metzger J, Fichtner A, Ruszai KH, Seemann T, Hansen M, Wygoda S, Krupka K, Tönshoff B, Melk A, Pape L.

Urinary proteomics to diagnose chronic active antibody-mediated rejection in pediatric kidney transplantation- a pilot study.

Transpl Int. 2018 Oct 25. doi: 10.1111/tri.13363. [Epub ahead of print]

PMID: 30357927

View Abstract:   Request Reprint

 

284.

Belczacka I, Pejchinovski M, Krochmal M, Magalhães P, Frantzi M, Mullen W, Vlahou A, Mischak H, Jankowski V.

Urinary Glycopeptide Analysis for the Investigation of Novel Biomarkers.

Proteomics Clin Appl. 2018 Oct 18:e1800111. doi: 10.1002/prca.201800111. [Epub ahead of print]

PMID: 30334612

View Abstract:   Request Reprint

 

283.

Huang QF, Van Keer J, Zhang ZY, Trenson S, Nkuipou-Kenfack E, Van Aelst LNL, Yang WY, Thijs L, Wei FF, Ciarka A, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.

Urinary proteomic signatures associated with β-blockade and heart rate in heart transplant recipients.

PLoS One. 2018 Sep 24;13(9):e0204439. doi: 10.1371/journal.pone.0204439. ECollection 2018.

PMID: 30248148

View Abstract:   Request Reprint

 

282.

Wallbach M, Zürbig P, Dihazi H, Müller GA, Wachter R, Beige J, Koziolek MJ, Mischak H.

Kidney protective effects of baroreflex activation therapy in patients with resistant hypertension.

J Clin Hypertens (Greenwich). 2018 Sep 10. doi: 10.1111/jch.13365. [Epub ahead of print]

PMID: 30203514

View Abstract:   Request Reprint

 

281.

Duranton F, Laget J, Gayrard N, Saulnier-Blache JS, Lundin U, Schanstra JP, Mischak H, Weinberger KM, Servel MF, Argilés A.

The CKD plasma lipidome varies with disease severity and outcome.

J Clin Lipidol. 2018 Aug 1. pii: S1933-2874(18)30350-7. doi: 10.1016/j.jacl.2018.07.010. [Epub ahead of print]

PMID: 30177483

View Abstract:   Request Reprint

 

280.

Latosinska A., Frantzi M., Merseburger AS, Mischak H,

Promise and Implementation of Proteomic Prostate Cancer Biomarkers.

Diagnostics (Basel). 2018 Aug 29:8(3). pii: E57. doi: 10.3390/diagnostics8030057. Review

PMID: 30158500

View Abstract:   Request Reprint

 

279.

Huang QF, Zhang ZY, Van Keer J, Trenson S, Nkuipou-Kenfack E, Yang WY, Thijs L, Vanhaecke J, Van Aelst LNL, Van Cleemput J, Janssens S, Verhamme P, Mischak H, Staessen JA.

Urinary peptidomic biomarkers of renal function in heart transplant recipients.

Nephrol Dial Transplant. 2018 Jul 2. doi: 10.1093/ndt/gfy185. [Epub ahead of print]

PMID: 29982668

View Abstract:   Request Reprint

 

278.

Belczacka I, Latosinska A, Metzger J, Marx D, Vlahou A, Mischak H, Frantzi M.

Proteomics biomarkers for solid tumors: Current status and future prospects.

Mass Spectrom Rev. 2018 Jun 11. doi: 10.1002/mas.21572. [Epub ahead of print] Review.

PMID: 29889308

View Abstract:  Request Reprint

 

277.

Huang QF, Trenson S, Zhang ZY, Van Keer J, Van Aelst LNL, Yang WY, Nkuipou-Kenfack E, Thijs L, Wei FF, Mujaj B, Ciarka A, Droogné W, Vanhaecke J, Janssens S, Van Cleemput J, Mischak H, Staessen JA.

Biomarkers to Assess Right Heart Pressures in Recipients of a Heart Transplant: A Proof-of-Concept Study.

Transplant Direct. 2018 Apr 23;4(5):e346. doi: 10.1097/TXD.0000000000000783. eCollection 2018 May.

PMID: 29796417

View Abstract:  Request Reprint

 

276.

Frantzi M, Latosinska A, Kontostathi G, Mischak H.

Clinical Proteomics: Closing the Gap from Discovery to Implementation.

Proteomics. 2018 Jul;18(14):e1700463. doi: 10.1002/pmic.201700463. Epub 2018 Jul 8.

PMID: 29785737

View Abstract:  Request Reprint

 

275.

Tofte N, Lindhardt M, Adamova K, Beige J, Beulens JWJ, Birkenfeld AL, Currie G, Delles C, Dimos I, Francová L, Frimodt-Møller M, Girman P, Göke R, Havrdova T, Kooy A, Mischak H, Navis G, Nijpels G, Noutsou M, Ortiz A, Parvanova A, Persson F, Ruggenenti PL, Rutters F, Rychlík I, Spasovski G, Speeckaert M, Trillini M, von der Leyen H, Rossing P.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes.

Diabet Med. 2018 May 21. doi: 10.1111/dme.13669. [Epub ahead of print]

PMID: 29781558

View Abstract:  Request Reprint

 

274.

Zhang ZY, Nkuipou-Kenfack E, Yang WY, Wei FF, Cauwenberghs N, Thijs L, Huang QF, Feng YM, Schanstra JP, Kuznetsova T, Voigt JU, Verhamme P, Mischak H, Staessen JA.

Epidemiologic observations guiding clinical application of a urinary peptidomic marker of diastolic left ventricular dysfunction.

J Am Soc Hypertens. 2018 Jun;12(6):438-447.e4. doi: 10.1016/j.jash.2018.03.007. Epub 2018 Mar 21.

PMID: 29681522

View Abstract:  Request Reprint

 

273.

Pejchinovski M, Mischak H.

Clinical Proteomics in Kidney Disease: From Discovery to Clinical Application.

Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Dec 1;38(3):39-54. doi: 10.2478/prilozi-2018-0005.

PMID: 29668468

View Abstract:  Request Reprint

 

272.

Lygirou V, Latosinska A, Makridakis M, Mullen W, Delles C, Schanstra JP, Zoidakis J, Pieske B, Mischak H, Vlahou A.

Plasma proteomic analysis reveals altered protein abundances in cardiovascular disease.

J Transl Med. 2018 Apr 17;16(1):104. doi: 10.1186/s12967-018-1476-9.

PMID: 29665821

View Abstract:  Request Reprint

 

271.

Currie GE, von Scholten BJ, Mary S, Flores Guerrero JL, Lindhardt M, Reinhard H, Jacobsen PK, Mullen W, Parving HH, Mischak H, Rossing P, Delles C.

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria.

Cardiovasc Diabetol. 2018 Apr 6;17(1):50. doi: 10.1186/s12933-018-0697-9.

PMID: 29625564

View Abstract:  Request Reprint

 

270.

Liu Y, Pejchinovski M, Wang X, Fu X, Castelletti D, Watnick TJ, Arcaro A, Siwy J, Mullen W, Mischak H, Serra AL.

Dual mTOR/PI3K inhibition limits PI3K-dependent pathways activated upon mTOR inhibition in autosomal dominant polycystic kidney disease.

Sci Rep. 2018 Apr 3;8(1):5584. doi: 10.1038/s41598-018-22938-x.

PMID: 29615724

View Abstract:  Request Reprint

 

269.

Magalhães P, Pontillo C, Pejchinovski M, Siwy J, Krochmal M, Makridakis M, Carrick E, Klein J, Mullen W, Jankowski J, Vlahou A, Mischak H, Schanstra JP, Zürbig P, Pape L.

Comparison of Urine and Plasma Peptidome Indicates Selectivity in Renal Peptide Handling.

Proteomics Clin Appl. 2018 Apr 3:e1700163. doi: 10.1002/prca.201700163. [Epub ahead of print]

PMID: 29611317

View Abstract:  Request Reprint

 

268.

Belczacka I, Latosinska A, Siwy J, Metzger J, Merseburger AS, Mischak H, Vlahou A, Frantzi M, Jankowski V.

Urinary CE-MS peptide marker pattern for detection of solid tumors.

Sci Rep. 2018 Mar 27;8(1):5227. doi: 10.1038/s41598-018-23585-y. [Epub ahead of print]

PMID: 29588543

View Abstract:  Request Reprint

 

267.

Marx D, Metzger J, Pejchinovski M, Gil RB, Frantzi M, Latosinska A, Belczacka I, Heinzmann SS, Husi H, Zoidakis J, Klingele M, Herget-Rosenthal S.

Proteomics and Metabolomics for AKI Diagnosis.

Semin Nephrol. 2018 Jan;38(1):63-87. doi: 10.1016/j.semnephrol.2017.09.007. Review.

PMID: 29291763

View Abstract:  Request Reprint